Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche - LARVOL DELTA

Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma. (PubMed, Sci Rep) - P2 | "The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden.Trial Registration: jRCT2011210029, NCT05007652."

Clinical • Journal • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • CD34

Large vessel vasculitis associated with atezolizumab. (PubMed, BMJ Case Rep) - "Existing literature has documented large vessel vasculitis in association with ipilimumab, pembrolizumab and nivolumab therapy. Although large vessel vasculitis was reported in one patient who had received both atezolizumab and pegfilgrastim, our patient represents the first instance of large vessel vasculitis associated with atezolizumab alone. Discontinuation of atezolizumab and tapered glucocorticoid therapy resulted in clinical and radiographic resolution."

Journal • Gastric Cancer • Hematological Disorders • Immunology • Myositis • Oncology • Rheumatology • Solid Tumor • Vasculitis

Comparing Filgrastim and Pegfilgrastim for Primary Prophylaxis of Febrile Neutropenia in Early Breast Cancer: A real-world study (ESMO-BC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • Febrile Neutropenia • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study (MBCC 2025) - P1, P3 | "Eflapegrastim—a novel, long-acting, recombinant human GCSF linked to human IgG4 Fc fragment—showed improved bone marrow residence vs pegfilgrastim that may allow for same-day dosing. Conclusion Eflapegrastim given on the same day as docetaxel and cyclophosphamide chemotherapy may reduce the time to ANC recovery and related complications in early-stage breast cancer. The AEs observed were consistent with those observed with other GCSF products."

Back Pain • Breast Cancer • Febrile Neutropenia • Hematological Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

STEM CELL MOBILIZATION WITH PEGFILGRASTIM IN PEDIATRIC PATIENTS FOR AUTOLOGOUS INFUSION: SAFE AND EFFECTIVE (EBMT 2025) - "PEGfilgrastim for stem cell mobilization was successful in all cases in our cohort. Nevertheless a substantial number of patients needed additional Filgrastim and/or Plerixafor. Therefore the protocol has been adjusted by increasing the dose of PEGfilgrastim (up to max."

Clinical • Bone Marrow Transplantation • Pediatrics • CD34

Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer. (PubMed, Anticancer Res) - "Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia."

Journal • Retrospective data • Breast Cancer • Cardiovascular • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - P1/2 | N=4 | Terminated | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jul 2025 ➔ Jul 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2025 ➔ Jul 2024; Administratively Complete 75%< Participants

Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • IL3RA

A Combined Therapy of Pegylated G-CSF with Ciprofloxacin Mitigates Damage Induced by Lethal Ionizing Radiation to the Bone Marrow, Spleen, and Ileum by Increasing AKT Activation but Decreasing IL-18, C3, and miR-34a. (PubMed, Radiat Res) - "Ciprofloxacin (CIP) was found to enhance pegylated G-CSF therapy (PEG, Neulasta®)-induced survival from 30% to 85% after ionizing radiation exposure. The results taken together suggest that PEG+CIP combined treatment was effective in mitigating the radiation-induced bone marrow, spleen, and ileum injury. The mitigative effect of this combined treatment was mediated by increases in G-CSF levels that suppress miR-34a, thereby probably leading to decreased gasdermin D-mediated pyroptosis."

IO biomarker • Journal • Cerebral Hemorrhage • Gastrointestinal Disorder • Hematological Disorders • BAX • BCL2 • CLDN2 • CSF3 • IL18 • MIR34A

Polyostotic Langerhans cell histiocytosis presenting as halitosis in a 24-year-old man: a case report. (PubMed, J Med Case Rep) - "This reveals the vitality of the early diagnosis of Langerhans cell histiocytosis to prevent disease progression. Awareness of diverse and nonpathognomonic manifestations of Langerhans cell histiocytosis, proper medical interview and history taking, and the use of routine radiographs may aid clinicians in lowering morbidity and mortality rates associated with such conditions."

Journal • Dental Disorders • Infectious Disease • Langerhans Cell Histiocytosis • Novel Coronavirus Disease • Oncology • Rare Diseases • Respiratory Diseases • CD1a

S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Cost-Effectiveness of Pegfilgrastim Versus 5-day Filgrastim in Early Breast Cancer Patients Undergoing Neoadjuvant and Adjuvant Chemotherapy: A Trial-Based Economic Evaluation (ISPOR 2025) - "PEG was associated with fewer hospitalizations, comparable FN incidence, and similar QLAYs compared to 5-day FIL, suggesting it may be the preferred option for EBC patients. A cost-effectiveness analysis is ongoing."

Clinical • Cost effectiveness • HEOR • Breast Cancer • Febrile Neutropenia • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

SINGLE DOSE PEGFILGRASTIM AND PLERIXAFOR IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT HIGH RISK OF MOBILIZATION FAILURE. EXPERIENCE OF A MEXICAN PUBLIC TRANSPLANT CENTER (EBMT 2025) - "The mobilization scheme with a single dose of Pegfilgrastim and Plerixafor resulted in an effectiveness rate of 77% of patients in our center, taking into consideration the patients high risk factors for failure and the history of failure to use filgrastim, an optimal count of CD34+ was achieved in the most patients; Therefore, this simplified scheme with few adverse effects is a factible scheme of movilization."

Clinical • Cardiovascular • CNS Disorders • Diabetes • Epilepsy • Hematological Disorders • Hematological Malignancies • Hypertension • Lymphoma • Metabolic Disorders • Multiple Myeloma • Oncology • Transplantation • CD34

REaCT-5G: A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy (clinicaltrials.gov) - P4 | N=233 | Completed | Sponsor: Ottawa Hospital Research Institute | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

Utility of pegfilgrastim for neutropenia with trifluridine/tipiracil plus bevacizumab therapy (JSMO 2025) - No abstract available

Oncology

Caught in the Crossfire: A Case of Splenic Infarction Amid G-CSF therapy in Chronic Myelomonocytic Leukaemia. (PubMed, Eur J Case Rep Intern Med) - "Clinical vigilance in G-CSF therapy This report highlights the need for heightened awareness of rare but severe complications, such as splenic infarction, associated with granulocyte-colony stimulating factor (G-CSF) therapy. Internists managing patients on chemotherapy must recognise early signs of such complications to optimise patient outcomes.Risk-benefit assessment It emphasises the importance of individualised treatment strategies, balancing the lifesaving benefits of G-CSF in preventing febrile neutropenia with the potential risks, particularly in patients with predisposing conditions such as chronic myelomonocytic leukaemia (CMML).Conservative management insights The successful non-surgical management of splenic infarction in this case underscores the potential for conservative approaches, providing valuable guidance for internists in similar clinical scenarios."

Journal • Chronic Myelomonocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Pain

Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management. (PubMed, Curr Treat Options Oncol) - "Several factors, such as high taxane dose, paclitaxel use, metastatic setting, breast cancer, younger age, and co-administration of pegfilgrastim, are associated with symptom development...Etoricoxib, a selective cyclooxygenase-2 inhibiting NSAID, also reduces the incidence and severity of T-APS...In contrast, evidence of symptomatic medication is limited. Taxanes are key chemotherapeutic agents used in the treatment of several types of cancer; therefore, further assessment of mechanisms of action and treatment of T-APS is necessary."

Journal • Review • Breast Cancer • Musculoskeletal Pain • Oncology • Pain • Peripheral Neuropathic Pain • Solid Tumor

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - P3 | N=244 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Sep 2027 ➔ Dec 2027 | Trial completion date: Sep 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov) - P1 | N=65 | Active, not recruiting | Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial primary completion date • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

The impact of the introduction of a pegfilgrastim autoinjector on medical staff's time spent writing medical record (JSMO 2025) - No abstract available

Oncology

Questionnaire for breast cancer patients and nurses on usage and satisfaction with pegfilgrastim automated dosing device (JSMO 2025) - No abstract available

Clinical • Breast Cancer • Oncology • Solid Tumor

Initiatives for the Introduction of G-LASTA® Subcutaneous Injection Body Pods (JSMO 2025) - No abstract available

Oncology

Real world usage of pegfilgrastim on-body injector for breast cancer patients: a retrospective, single-institution study (JSMO 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Breast Cancer • Oncology • Solid Tumor

Omission of pegfilgrastim in perioperative dose-dense paclitaxel therapy for breast cancer (JSMO 2025) - No abstract available

Breast Cancer • Oncology • Solid Tumor

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma. (PubMed, Transfus Apher Sci) - "EAP is an excellent mobilization regimen with acceptable toxicity and could be considered in patients with MM and lymphoma with poor mobilization."

Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • Transplantation • CD34

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=31 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Initiation date: Dec 2024 ➔ Jun 2025

Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology